Loading company…
Taifeier biomedical researches and develops small molecule drugs.
Taifeier biomedical researches and develops small molecule medicines for inflammatory, autoimmune, cardiovascular, and metabolic diseases, as well as depression. Founded in 2004, the company is based in Suzhou, China. In August 2021, it raised Series B funding led by CAS Investment Management, with participation from SND Ventures Group, Tasly Holding Group, Greatwall Fund, and Junchuan Capital, to support clinical trials and research operations.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in